Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)
Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available, especially for the advent of new targeted drugs and immune checkpoint inhibitors which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association revised the 2018 version of the guideline to adapt to the development of PVTT treatment. Futu...
Source: Liver Cancer - March 17, 2022 Category: Cancer & Oncology Source Type: research

Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumour thrombus in China (2021 edition)
Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the Guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available especially for the advent of new targeted drugs and immune checkpoint inhibitor (ICIs) which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer (CALC) and Chinese Medical Doctor Association(CMDA) revised the 2018 version of guideline to adapt to the development of PVTT t...
Source: Liver Cancer - March 17, 2022 Category: Cancer & Oncology Source Type: research

Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with unresectable, advanced hepatocellular carcinoma: A real-world, multicenter, retrospective study
Introduction: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC). We aimed to compare the clinical outcomes of lenvatinib plus drug-eluting beads transarterial chemoembolization (DEB-TACE) versus lenvatinib alone in real-world practice. Methods: This retrospective analysis included 142 consecutive patients who received lenvatinib plus DEB-TACE and 69 patients who received lenvatinib alone as first-line treatment from 15 Chinese academic centers from Nov 2018 to Nov 2019. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) evaluated by mRECIST criteria, and s...
Source: Liver Cancer - March 9, 2022 Category: Cancer & Oncology Source Type: research

Liver Cancer Study Group of Japan clinical practice guidelines for intrahepatic cholangiocarcinoma
This paper presents the first version of clinical practice guidelines for intrahepatic cholangiocarcinoma (ICC) established by the Liver Cancer Study Group of Japan. These guidelines consist of 1 treatment algorithm, 5 background statements, 16 clinical questions, and 1 clinical topic, including etiology, staging, pathology, diagnosis, and treatments. Globally, high incidence of ICC has been reported in East and Southeast Asian countries and the incidence has been gradually increasing in Japan and also in Western countries. Reported risk factors for ICC include cirrhosis, hepatitis B/C, alcohol consumption, diabetes, obesi...
Source: Liver Cancer - February 23, 2022 Category: Cancer & Oncology Source Type: research

Management of systemic therapies and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma based on sarcopenia assessment
Background: Sarcopenia, defined as the loss of skeletal muscle mass, physical performance, and strength, has been associated with poor clinical outcomes in hepatocellular carcinoma (HCC) patients treated with several therapies. As systemic therapies, including molecular targeted agents, have a strong impact on sarcopenia, we aimed to review the impact of sarcopenia in patients receiving systemic therapies, especially sorafenib and hepatic arterial infusion chemotherapy (HAIC). Summary: Several studies have demonstrated that sarcopenia is associated with poor clinical outcomes in patients receiving sorafenib or lenvatinib,...
Source: Liver Cancer - February 22, 2022 Category: Cancer & Oncology Source Type: research

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
N/A (Source: Liver Cancer)
Source: Liver Cancer - February 18, 2022 Category: Cancer & Oncology Source Type: research

Objective response by mRECIST to initial lenvatinib therapy is an independent factor contributing to deep response in hepatocellular carcinoma treated with lenvatinib-transcatheter arterial chemoembolization sequential therapy
In this study, at eight weeks after resumption of LEN after initial TACE, "deep response" was defined as achieving CR or PR on mRECIST, and at least a 30% decrease in the sum of diameters of target lesions, taking the baseline sum diameters as the reference. Results: The OS and PFS in the LEN-TACE group were significantly higher than those in the LEN monotherapy group (P = 0.002 and P = 0.037, respectively). The incidence of AEs related to LEN was not significantly different between the two groups. In LEN-TACE sequential therapy, the objective response rate was 61.9%, and the disease control rate was 74.6%, according to t...
Source: Liver Cancer - February 15, 2022 Category: Cancer & Oncology Source Type: research

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
Conclusion: Based on a favorable safety profile, exposure, and preliminary signal of activity, oral GNS561 RP2D was set at 200 mg BID. Studies to evaluate the antitumor activity of GNS561 in hepatocarcinoma cells and intrahepatic cholangiocarcinoma are to follow NCT 03316222. (Source: Liver Cancer)
Source: Liver Cancer - February 15, 2022 Category: Cancer & Oncology Source Type: research

First-in-human effects of PPT1 inhibition using the oral treatment with GNS561/ Ezurpimtrostat in patients with primary and secondary liver cancers
Conclusion - Based on a favourable safety profile, exposure, and preliminary signal of activity, oral GNS561 RP2D was set at 200mg BID. Studies to evaluate the antitumor activity of GNS561 in HCC and iCCA are to follow. NCT 03316222 (Source: Liver Cancer)
Source: Liver Cancer - February 15, 2022 Category: Cancer & Oncology Source Type: research

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Conclusions In TACTICS trial, TACE plus sorafenib did not show significant OS benefit over TACE alone; however, clinical meaningful OS prolongation and significantly improved PFS was observed. Thus, the TACE plus sorafenib can be considered a choice of treatment in intermediate stage HCC, especially in patients with high tumor burden. Trial Registration: NCT01217034 (Source: Liver Cancer)
Source: Liver Cancer - February 10, 2022 Category: Cancer & Oncology Source Type: research

AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review
Background: Multikinase inhibitors (MKIs) have been shown to improve survival in patients with hepatocellular carcinoma (HCC) compared with placebo. Distinct from other MKIs, cabozantinib has inhibitory activity for both AXL and MET. This review considers the literature elucidating the role of AXL and MET in HCC progression, treatment resistance, and immunomodulation. A systematic search of the PubMed database was conducted on November 16, 2020, and identified a total of 174 search results. A further 36 potentially relevant articles were identified based on the authors ’ knowledge. After initial screening by title/abstra...
Source: Liver Cancer - February 10, 2022 Category: Cancer & Oncology Source Type: research

Period-Dependent Survival Benefit of Percutaneous Microwave Ablation for Hepatocellular Carcinoma: A 12-Year Real-World, Multicentric Experience
Conclusions: These real-world data show that MWA provided an upward trend in survival for HCC patients with BCLC stage 0 –B over a 12-year follow-up period. An encouraging clear survival benefit in early recurrent patients was also observed. (Source: Liver Cancer)
Source: Liver Cancer - January 28, 2022 Category: Cancer & Oncology Source Type: research

Period-dependent survival benefit of percutaneous microwave ablation for hepatocellular carcinoma: 12-year real-world multicentric experience
Introduction: Although being a promising technique for hepatocellular carcinoma (HCC) treatment, the 10-year efficacies of microwave ablation (MWA) are unknown. Objective: To assess whether the advances of MWA for HCC translated into a real-world survival benefit. Methods: This retrospective study included 2,354 patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 to B from 5 hospitals, with at least 2 years of follow-up for all the patients. Recurrence and survival were analyzed using the Kaplan-Meier method with time-period stratification. Results: A total of 5,326 HCCs (mean diameter, 2.9 cm ± 1.2) underwent 4...
Source: Liver Cancer - January 28, 2022 Category: Cancer & Oncology Source Type: research

A hybrid machine learning model based on semantic information can optimize treatment decision for na ïve single 3-5cm HCC patients
Abstract: Background: Tumor recurrence is an abomination for hepatocellular carcinoma (HCC) patients receiving local treatment. Purpose: To build a hybrid machine learning model to recommend optimized first treatment (Laparoscopic hepatectomy (LH) or Microwave ablation (MWA)) for na ïve single 3-5cm HCC patients based on early recurrence (ER, ≤2 years) probability. Methods: This retrospective study collected 20 semantic variables of 582 patients (LH:300, MWA:282) from 13 hospitals with at least 24 months follow-up. Both groups were divided into training, validation and test set, respectively. Five algorithms (Logistic...
Source: Liver Cancer - January 28, 2022 Category: Cancer & Oncology Source Type: research

Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma
Conclusion Genetic variant of CXCR1 +860 C>G may serve as a molecular marker for DFS, CSS and OS in patients undergoing curative-intent surgery for pCCA, indicating that the analysis of SNPs in genes involved in immune-mediated angiogenesis may help to identify patient subgroups at high risk for dismal oncological and overall outcome. (Source: Liver Cancer)
Source: Liver Cancer - January 25, 2022 Category: Cancer & Oncology Source Type: research